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Developments in Biologicals Authoritative reports on the development and use of standardized biologicals
The International Association for Biologicals organizes international meetings which confront the numerous practical problems involved in standardization and bring together researchers, manufacturers, public health authorities and government offi cials. Books in this series, which record these meetings, are respected as defi nitive references to current work on international biological standards, biological reference preparations and biological reference reagents. T T  TATCCAATGATAAGCATCACGGTAT ATCCAATGATAAGCATGATAAGCTCACGGTATCCAA AATGATAAGCATCACGGT  AGCATGATAAGCTCACGGTATCCAAT ATGATAAGCATCACGGTATCCAATGATAAGCATGAT ATAAGCTCACGGTATC  G  AGCATCACGGTATCCAATGATAAGCAT TGATAAGCGT G  ATCCAATGATAAGCATCACGGTATCC CCAATGATAAGCATG  G  GGTATCCAATGATAAGCATCACGGTATCC CAATGATAAGCATGATAAGCCACGGTATCCAATGA GATAAGCATCACG  G  GATAAGCATGATAAGCTCACGGTATCCAATG TGATAAGCATCACGGTATCCAATGATAAGCATGATA TAAGCTCACGG  A  AGCATCACGGTATCCAATGATAAGCATGATAA AGCTCACGGTATCCAATGATAAGCATCACGGTATC TCCAATGATAA  A  AGCTCACGGTATCCAATGATAAGCATCACGGTAT ATCCAATGATAAGCATGATAAGCTCACGGTATCCA AATGATAA  G G  TATCCAATGATAAGCATGATAAGCTCACGGTATCCA CAATGATAAGCATCACGGTATCCAATGATAAGCAT ATGATAAG  C  CAATGATAAGCATCACGGTATCCAATGATAAGCATG GATAAGCTCA A  CGGTATCCAATGATAAGCATCACGG GGTATC  AGCATGATAAGCTCACGGTATCCAATGATAAGCATCAC ACGGTATCCAATGATAAGCATGATAAGCTCACGGTA TATC  A  AGCATCACGGTATCCAATGATAAGCATGATAAGCTCACGG GGTATCCAATGATAAGCATCACGGTATCCAATGA ATA TAA  A  AGCTCACGGTATCCAATGATAAGCATCACGGTATCCAATGA GATAAGCATGATAAGCTCACGGTATCAGCATGATA A  T  TATCCAATGATAAGCATCACGGTATCCAATGATAAGCATGATA TAAGCTCACGGTATCCAATGATAAGCATCACGGT  AGCATGATAAGCTCACGGTATCCAATGATAAGCATCACGGTATC TCCAATGATAAGCATGATAAGCTCACGGTATC  A  AGCATCACGGTATCCAATGATAAGCATGATAAGCTCACGGTATCC CAATGATAAG A  CATCACGGTATCCAATGATAA  G G  AGCTCACGGTATCCAATGATAAGCATCACGGTATCCAATGATAAGCA CATGATAAGTCACGGTATCCAATGATAAG  G  TATCCAATGATAAGCATGATAAGCTCACGGTATCCAATGATAAGCATCA CACGGTATCCAATGATAAGCATGATAAG  C  CAATGATAAGCATCACGGTATCCAATGATAAGCATGATAAGCTCACGGTA TATCCAATGATAAGCATCACGGTATC  C  AGCATGATAAGCCACGGTATCCAATGATAAGCATCACGGTATCCAATGATAA TAAGCATGATAAGCTCACGGTATCC  A  AGCATCACGGTATCCAATGATAAGCATGATAAGCTCACGGTATCCAATGATAA AAGCATCACGGTATCCAATGATAA  A  AGCTCACGGTATCCAATGATAAGCATCACGGTATCCAATGATAAGCATGATAAG AGCTCACGGTATCCAATGATAA  G  TATCCAATGATAAGCATGATAAGCTCACGGTATCCAATGATAAGCATCACGGTATC TCCAATGATAAGCATGATAAG  C  CAATGATAAGCATCACGGTATCCAATGATAAGCATGATAAGCTCACGGTATCCAATG TGATAAGCATCACGGTATC  AGCATGATAAGCTCACGGTATCCAATGATAAGCATCACGGTATCCAATGATAAGCATGA GATAAGCTCACGGTATC  A A  AGCATCACGGTATCCAATGATAAGCATGATAAGCTCACGGTATCCAATGATAAGCATCAC ACGGTATCCAATGATAA  A  AGCTCACGGTATCCAATGATAAGCATCACGGTATCCAATGATAAGCATGATAAGCTCACGG GTATCCAATGATAA  G  TATCCAATGATAAGCATGATAAGCTCACGGTATCCAATGATAAGCATCACGGTATCCAATGAT ATAAGCATGAT A  AAG  C  CAATGATAAGCATCACGGTATCCAATGATAAGCATGATAAGCTCACGGTATCCAATGATAAGCAT ATCACGGTATC  AGCATGATAAGCGTATCCAATGATAAGCATCACGGTATCCAATGATAAGCATGATAAGCTCACGGT GTATCCAATG  A  GGTATCCAATGATAAGCATGATAAGCCACGGTATCCAATGATAAGCATCACGGTATCCAATGATAAGC GCATGATAA  T  TATCCAATGATAAGCATCACGGTATCCAATGATAAGCATGATAAGCTCACGGTATCCAATGATAAGCAT ATCACGGT  AGCATGATAAGCTCACGGTATCCAATGATAAGCATCACGGTATCCAATGATAAGCATGATAAGCTCACGG GTATC  A  AGCATCACGGTATCCAATGATAAGCATGATAAGCTCACGGTATCCAATGATAAGCATCACGGTATCCAATGA GATAA  A  AGCTCACGGTATCCAATGATAAGCATCACGGTATCCAATGATAAGCATGATAAGCTCACGGTATCCAATGAT TAA A  G  TATCCAATGATAAGCATGATAAGCTCACGGTATCCAATGATAAGCATCACGGTATCCAATGATAAGCATGATAAG AG  CAATGATAAGCATCACGGTATCCAATGATAAG  AGCATGATAAGCTCACGGTATCCAATGATAAGCATCACGGTATCCAATGATAAGCATGATAAGCTCACGGTATC  A  AGCATCACGGTATCCAATGATAAGCATGATAAGCTCACGGTATCCAATGATAAGCATCACGGTATCCAATGATAA  A  AGCTCACGGTATCCAATGATAAGCATCACGGTATCCAATGATAAGCATGATAAGCTCACGGTATCCAATGATAA  G  TATCCAATGATAAGCATGATAAGCTCACGGTATCCAATGATAAGCATCACGGTATCCAATGATAAGCATGATAAG  C  CAATGATAAGCATCACGGTATCCAATGATAAGCATGATAAGCTCACGGTATCCAATGATAAGCATCACGGTATC  C  AGCATGATAAGCTCACGGTATCCAATGATAAGCATCACGGTATCCAATGATAAGCATGATAAGTCACGGTATCC  A  AGCATCACGGTATCCAATGATAAGCATGATAAGCTCACGGTATCCAATGATAAGCATCACGGTATCCAATGATAA  G G  AGCCACGGTATCCAATGATAAGCATCACGGTATCCAATGATAAGCATGATAAGCTCACGGTATCCAATGATAAG  G  TATCCAATGATAAGCATGATAAGCTCACGGTATCCAATGATAAGCATCACGGTATCCAATGATAAGCATGATAAG  C  CAATGATAAGCATCACGGTATCCAATGATAAGCATGATAAGCTCACGGTATCCAATGATAAGCATCACGGTATC  AGCATGATAAGCTCACGGTATCCAATGATAAGCATCACGGTATCCAATGATAAGCATGATAAGCTCACGGTATC  A  TGATAA  A  ATCCA  G  GATAAGCTCACGGTATCCAATGATAAGCATCACGGTATCCAATGATAAGCATGATAAGCTCACGGTATCCAATG  A  GGTATCCAATGATAAGCATGATAAGCTCACGGTATCCAATGATAAGCATCACGGTATCCAATGATAAGCATGATA  T  TATCCAATGATAAGCATCACGGTATCCAATGATAAGCATGATAAGCTCACGGTATCCAATGATAAGCATCACGGT  AGCATGATAAGCTCACGGTATCCAATGATAAGCATCAC  AGCATCACGGTATCCAATGATAAGCATGATAAGCGTAT  G  GGTATCCAATGATAAGCATCACGGTATCCAATGATAAGCATGATAAGCCACGGTATCCAATGATAAGCATCACG  G G  GATAAGCATGATAAGCTCACGGTATCCAATGATAAGCATCACGGTATCCAATGATAAGCATGATAAGCTCACGG  A  AGCATCACGGTATCCAATGATAAGCATGATAAGCTCACGGTATCCAATGATAAGCATCACGAGTATCCAATGATA  A  AGCTCACGGTATCCAATGATAAGCATCACGGTATCCAATGATAAGCATGATAAGCTCACGGTATCCAATGATAA  G  TATCCAATGATAAGCATGATAAGCTCACGGTATCCAATGATAAGCATCACGGTATCCAATGATAAGCATGATAAG  C  CAATGATAAGCATCACGGTATCCAATGATAAGCATGATAAGCTCACGGTATCCAATGATAAGCATCACGGTATC  AGCATGATAAGCTCACGGTATCCAATGATAAGCATCACGGTATCCAATGATAAGCATGATAAGCTCACGGTATC  A In well-referenced chapters, experts cogently and concisely explain how the incorporation of gender issues into research can affect the medical understanding and treatment of heart disease, osteoporosis, arthritis, pain as well as malaria among other conditions. This intriguing and unique medical textbook provides readers with a valuable new perspective on how to incorporate gender issues into the different branches of medicine.
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The search for innovative and eff ective drugs begins here
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